Adult Congenital Heart Disease Program, Cardiology Division, NYU Langone Health, New York, New York.
Adult Congenital Heart Disease Program, Cardiology Division, NYU Langone Health, New York, New York.
J Am Coll Cardiol. 2019 Feb 5;73(4):457-476. doi: 10.1016/j.jacc.2018.10.075.
Cardiovascular disease complicating pregnancy is rising in prevalence secondary to advanced maternal age, cardiovascular risk factors, and the successful management of congenital heart disease conditions. The physiological changes of pregnancy may alter drug properties affecting both mother and fetus. Familiarity with both physiological and pharmacological attributes is key for the successful management of pregnant women with cardiac disease. This review summarizes the published data, available guidelines, and recommendations for use of cardiovascular medications during pregnancy. Care of the pregnant woman with cardiovascular disease requires a multidisciplinary team approach with members from cardiology, maternal fetal medicine, anesthesia, and nursing.
心血管疾病合并妊娠的发病率上升，这与产妇年龄增长、心血管危险因素以及先天性心脏病治疗水平提高有关。妊娠的生理变化可能改变药物特性，从而影响母亲和胎儿。熟悉生理和药理学特性是成功管理患有心脏病的孕妇的关键。本综述总结了目前已发表的数据、相关指南和心血管药物在妊娠期间使用的建议。患有心血管疾病的孕妇需要多学科团队的治疗，团队成员包括心脏病学、母胎医学、麻醉学和护理学专家。
